SuperworthElanco Animal Health ELAN
- Market cap
- $11.3B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.2×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $5B
- +12% on a year ago
- Net margin
- −4.0%
- Free cash flow yield
- 3.4%
Elanco Animal Health trades at 2.2× sales. Its trailing earnings are negative, so it has no PE. Revenue was $5B over the last twelve months, up 12% on a year earlier with a −4% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.1B+4% | $1B+5% | $1.2B−4% | $1.2B+12% | $1B−4% | $1B−1% | $1.2B−1% | $1.2B+5% | $1.1B+10% | $1.1B+12% | $1.4B+15% | $1.4B+10% | |
| Cost of revenue | $487M+3% | $516M+15% | $515M+4% | $495M+14% | $492M+1% | $501M−3% | $509M−1% | $528M+7% | $530M+8% | $555M+11% | $586M+15% | $570M+8% |
| Gross profit | $581M+5% | $519M−3% | $690M−10% | $689M+11% | $538M−7% | $519M+0% | $684M−1% | $713M+4% | $607M+13% | $589M+14% | $785M+15% | $798M+12% |
| R&D | $86M+10% | $79M−1% | $87M+7% | $89M+10% | $87M+1% | $81M+3% | $94M+8% | $92M+3% | $89M+2% | $93M+15% | $97M+3% | $92M+0% |
| SG&A | $313M+5% | $292M−3% | $337M+3% | $354M+0% | $323M+3% | $300M+3% | $341M+1% | $400M+13% | $351M+9% | $338M+13% | $381M+12% | $449M+12% |
| −$1B | −$26M+333% | $87M−52% | $35M+94% | −$22M−98% | $1M | $112M+29% | $84M+140% | $2M | −$183M | $153M+37% | $109M+30% | |
| Interest expense | $72M+20% | $67M+8% | $66M+3% | $65M−12% | $58M−19% | $46M−31% | $40M−39% | $48M−26% | $52M−10% | $80M+74% | $57M+43% | $59M+23% |
| Pre-tax income | −$1.1B+2393% | −$127M+43% | $12M−89% | −$32M−60% | $559M | −$51M−60% | $60M+400% | $25M | −$50M | −$259M+408% | $87M+45% | $56M+124% |
| −$1M | $14M | −$20M | $18M+0% | $195M | −$43M | −$7M−65% | $14M−22% | −$16M | $17M | $30M | $2M−86% | |
| Net income | −$1.1B+1586% | −$141M+161% | $32M−69% | −$50M−49% | $364M | −$8M−94% | $67M+109% | $11M | −$34M | −$276M+3350% | $57M−15% | $54M+391% |
| −$2.22+1608% | −$0.29+164% | $0.06−71% | −$0.10−50% | $0.73 | −$0.02−93% | $0.13+117% | $0.02 | −$0.07 | −$0.56+2700% | $0.11−15% | $0.11+450% | |
| 492.7M+1% | 492.9M+1% | 496M+1% | 494.2M+0% | 497.7M+1% | 494.3M+0% | 499.1M+1% | 500.1M+1% | 496.8M−0% | 497M+1% | 506M+1% | 505.9M+1% |
Gross profit: 32 periods, Q1 FY17 to Q4 FY24: not printed by the filing, worked out from its own lines.
Operating income: 38 periods, Q1 FY17 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 10 periods, Q4 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY17: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x1.214). Q4 FY18: share-days: the 12-month average less the 9-month, weighted by days. 7 periods, Q4 FY19 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Elanco Animal Health's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ELANElanco Animal Health | $11.3B | n/m | 100× | 2.2× | +12% | −4.0% | |
| BMRNBiomarin Pharmaceutical | $10.8B | 151× | 70.6× | 3.2× | +11% | 2.1% | |
| CORTCorcept Therapeutics | $9.3B | 204× | 28.3× | 11.2× | +16% | 6.6% | |
| JAZZJazz Pharmaceuticals | $13.9B | 14.6× | 20.2× | 3.0× | +13% | 20.4% | |
| PTGXProtagonist Therapeutics | $9B | 134× | 58.3× | 31.8× | +35% | 29.4% | |
| TGTXTG Therapeutics | $8.3B | 19.8× | 19.4× | 10.4× | +76% | 55.2% | |
| ALKSAlkermes plc. | $7.3B | 115× | 16.0× | 4.4× | +11% | 4.0% | |
| AMRXAmneal Pharmaceuticals | $6.5B | 41.6× | 51.5× | 2.1× | +9% | 5.0% | |
| LGNDLigand Pharmaceuticals | $6.1B | 32.3× | 37.7× | 20.8× | +55% | 67.9% | |
| KNSAKiniksa Pharmaceuticals International | $6B | 79.1× | 85.3× | 7.1× | +59% | 9.6% | |
| INDVIndivior Pharmaceuticals | $4.1B | 12.4× | 20.1× | 3.1× | +13% | 26.7% | |
| Peer median | $7.8B | 60.3× | 33.0× | 5.8× | +15% | 15.0% |
Investors who own it
Investors we follow who held Elanco Animal Health at the end of Jun 30, 2026, from their 13F filings.
- Lee AinslieMaverick Capital0.0% of portfoliotrimmed
- Ron BaronBaron Capital0.0% of portfoliotrimmed
More on Elanco Animal Health
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .